Structure via PubChem · Public domain (PubChem)
tetraxetan
Sign in to saveAlso known as NSC 681107, 1,4,7,10-Dota, ,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid, 2,2',2',2'''-(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetryl)tetraacetic acid, 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, DOTA acid
chemical compound
Chemical data
- Formula
- C16H28N4O8
- Molecular weight
- 404.42 g/mol
- IUPAC name
- 2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
- SMILES
- C1CN(CCN(CCN(CCN1CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O
- InChIKey
- WDLRUFUQRNWCPK-UHFFFAOYSA-N
- XLogP
- -10.6
- Polar surface area
- 162 Ų
- H-bond donors
- 4
- H-bond acceptors
- 12
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- acute lymphoblastic leukemia, diffuse large B-cell lymphoma, neuroendocrine neoplasm, carcinoma
via ChEMBL · EBI
Research
1,554 papers- FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
- Lutetium Lu 177 vipivotide tetraxetan for prostate cancer.Drugs of today (Barcelona, Spain : 1998) · 2023
- Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.Molecular diagnosis & therapy · 2022
- Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer.Expert review of anticancer therapy · 2022
- (177)Lu-Vipivotide Tetraxetan ((177)Lu-PSMA-617, Pluvicto) Therapy.Journal of nuclear medicine technology · 2022
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has part
- hydrogen
- Mass
- 404.190714
Show 2 more facts
- chemical formula
- C₁₆H₂₈N₄O₈
- canonical SMILES
- C1CN(CCN(CCN(CCN1CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O
via Wikidata · CC0